BidaskClub upgraded shares of Access Pharmaceuticals (NASDAQ:ABEO) from a hold rating to a buy rating in a research note released on Saturday morning.
Several other research analysts have also recently weighed in on ABEO. HC Wainwright set a $30.00 price target on shares of Access Pharmaceuticals and gave the company a buy rating in a research report on Thursday, January 4th. Royal Bank of Canada reissued a buy rating and set a $26.00 price target on shares of Access Pharmaceuticals in a research report on Wednesday, January 24th. ValuEngine raised shares of Access Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, February 2nd. Maxim Group reissued a buy rating and set a $35.00 price target on shares of Access Pharmaceuticals in a research report on Wednesday, February 7th. Finally, Cantor Fitzgerald set a $36.00 price target on shares of Access Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, March 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $28.88.
Shares of ABEO stock opened at $20.10 on Friday. The stock has a market cap of $932.73, a PE ratio of -30.45 and a beta of 1.29. Access Pharmaceuticals has a twelve month low of $4.55 and a twelve month high of $22.75.
Access Pharmaceuticals (NASDAQ:ABEO) last announced its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.24 million. Access Pharmaceuticals had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. Access Pharmaceuticals’s revenue for the quarter was down 16.0% on a year-over-year basis. analysts expect that Access Pharmaceuticals will post -0.79 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of ABEO. Teacher Retirement System of Texas purchased a new stake in Access Pharmaceuticals in the 4th quarter valued at about $163,000. MetLife Investment Advisors LLC purchased a new stake in Access Pharmaceuticals in the 4th quarter valued at about $194,000. SG Americas Securities LLC purchased a new stake in Access Pharmaceuticals in the 4th quarter valued at about $218,000. Virtu Financial LLC purchased a new stake in Access Pharmaceuticals in the 4th quarter valued at about $246,000. Finally, California State Teachers Retirement System purchased a new stake in Access Pharmaceuticals in the 2nd quarter valued at about $275,000. Hedge funds and other institutional investors own 62.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/access-pharmaceuticals-abeo-raised-to-buy-at-bidaskclub.html.
Access Pharmaceuticals Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Receive News & Ratings for Access Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Access Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.